Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn’s disease

Rajesh Shah

doi:10.1080/08998280.2026.2686024

June 15, 2026Baylor University Medical Center Proceedings

Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn’s disease

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to compare the effectiveness of ustekinumab and vedolizumab for treating moderate to severe Crohn's disease.
Study comparing ustekinumab and vedolizumab
Patients with moderate to severe Crohn's disease were enrolled
Outcomes assessed include clinical remission and adverse events
Ustekinumab showed a higher rate of clinical remission at 24 weeks (65%) compared to vedolizumab (52%), p=0.02.
Adverse events were reported at similar rates for both treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Compares ustekinumab and vedolizumab effectiveness in Crohn's disease, suggesting optimal biologic choices.

Abstract

Selecting the optimal biologic for patients with moderate to severe Crohn’s disease (CD) is one of the most consequential decisions in gastroenterology practice. The 2025 American Gastroenterologic...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rajesh Shah (2026) studied this question.

synapsesocial.com/papers/6a323e9ed50b63ecad207bd9 https://doi.org/10.1080/08998280.2026.2686024

View at Publisher

Ask AI

Bookmark

Share

Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn’s disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Bridging the gap between guidelines and practice: comparative effectiveness of ustekinumab and vedolizumab in Crohn’s disease

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading